West Pharmaceutical Services, Inc. WST
412.86 USD +0.31 (+0.08%)
At closeNov 11, 2026, 5:25 PM EST
412.86 0.00 0.00%
After hours · Nov 11, 5:25 PM ET
411.86 Day range 415.85
230.95 52-week range 416.67
- YTD
- +50.05%
- 1 year
- +48.83%
News
defenseworld.net Candriam S.C.A. Purchases 3,140 Shares of West Pharmaceutical Services, Inc. $WST Candriam S.C.A. boosted its position in West Pharmaceutical Services, Inc. (NYSE: WST) by 3.3% during the undefined quarter, according to the company in its most recent filing with the Securities and…
zacks.com West Pharmaceutical Services (WST) is a Great Momentum Stock: Should You Buy? Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.
prnewswire.com West to Participate in Upcoming Investor Conference EXTON, Pa., Nov. 4, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will…
defenseworld.net West Pharmaceutical Services, Inc. $WST Stock Position Raised by Bank Julius Baer & Co. Ltd Zurich Bank Julius Baer and Co. Ltd Zurich increased its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 39.8% in the undefined quarter, according to the company in its most recent…
marketbeat.com What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call West Pharmaceutical Services NYSE: WST reported third-quarter results that exceeded its expectations, driven by continued demand for high-value product components, including those used in GLP-1…
benzinga.com Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494 Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $412 to $494.
benzinga.com TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500 TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $420 to $500.
benzinga.com Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500 Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.- benzinga.com Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480 Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $440 to $480.
seekingalpha.com West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript
zacks.com West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised WST reports strong Q3 earnings and revenue growth, fueled by high-value products and margin expansion, and raises its 2026 sales and earnings outlook.
zacks.com Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare…
benzinga.com West Pharmaceutical Servs Q3 2026 Earnings Call Transcript West Pharmaceutical Servs (NYSE:WST) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates West Pharmaceutical Services (WST) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.18 per share. This compares to earnings of $1.96 per share a year…
benzinga.com West Pharmaceutical Servs Sees Q4 Adj EPS $2.22-$2.32 vs $2.27 Est; Sees Sales $820.000M-$830.000M vs $826.736M Est West Pharmaceutical Servs (NYSE:WST) is looking for Q4 Adj EPS of $2.22-$2.32 vs $2.27 analyst estimate. sees sales of $820.000 million-$830.000 million vs $826.736 million analyst estimate.
benzinga.com West Pharmaceutical Servs Q3 Adj. EPS $2.66 Beats $2.19 Estimate, Sales $874.500M Beat $825.700M Estimate West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $2.19 by 21.46 percent. This is a 35.71 percent increase over earnings…- benzinga.com West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $9.01-$9.26 to $9.31-$9.41 vs $8.47 Est West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $9.01-$9.26 to $9.31-$9.41 vs $8.47 analyst estimate..
prnewswire.com West Reports Third-Quarter 2026 Results Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance EXTON, Pa., Oct. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality…
zacks.com West Pharmaceutical (WST) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates Get a deeper insight into the potential performance of West Pharmaceutical (WST) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the…
zacks.com WST Q3 Earnings Preview: Will HVP Strength Offset Vantage Weakness? WST's Q3 earnings may benefit from strong HVP demand, biologics and GLP-1 growth, but West Vantage weakness and the SmartDose divestiture could weigh on sales.
zacks.com Reasons to Add West Pharmaceutical Stock to Your Portfolio Now West Pharmaceutical???s biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
prnewswire.com West Declares Quarterly Dividend EXTON, Pa., Oct. 19, 2026 /PRNewswire/ -- On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug…
benzinga.com This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History Ball Corp stock is on an 11-day winning streak, its longest since NYSE trading began in 1973, while the S&P 500 has slipped. Here is what the data shows.
zacks.com West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally? West Pharmaceutical Services WST shares have gained 36.1% year to date, significantly outperforming its industry's advancement of 7.8%. The rally reflects improving demand for high-value…
defenseworld.net West Pharmaceutical Services (NYSE:WST) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell? West Pharmaceutical Services, Inc. (NYSE: WST - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving…
benzinga.com Meta, JPMorgan, West Pharmaceutical And More: CNBC's ‘Final Trades' On CNBC's “Halftime Report Final Trades,” Joseph M. Terranova, senior managing director for Virtus Investment Partners, said he likes West Pharmaceutical Services, Inc. (NYSE:WST).
benzinga.com Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’ CNBC traders picked WST, JPM, META and IYE; analysts raised WST and META targets, while JPM missed Q3 earnings and revenue estimates.
benzinga.com TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420 TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $410 to $420.
seekingalpha.com Top 50 High-Quality Dividend Growth Stocks For October 2026 I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home…
prnewswire.com West to Host Third-Quarter 2026 Conference Call EXTON, Pa., Oct. 8, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will…- benzinga.com Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440 Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.
seekingalpha.com West Pharma: Still A Buy, But Expectations Are Rising West Pharmaceutical Services remains a buy despite a demanding valuation, driven by new growth catalysts and robust financial performance. Double-digit growth from GLP-1s, HVP upgrades, and the…
benzinga.com This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Analysts upgraded MetLife, Brinker, Plexus, West Pharma and Omeros, raising ratings and price targets.- benzinga.com Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400 Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.
benzinga.com UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415 UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.
benzinga.com Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412 Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $400 to $412.
benzinga.com Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425 Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $410 to $425.
benzinga.com West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.
benzinga.com Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call West Pharmaceutical Servs (NYSE:WST) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs…
benzinga.com Earnings Scheduled For July 23, 2026 Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is…- benzinga.com West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est West Pharmaceutical Servs (NYSE:WST) raises FY2026 Adj EPS guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 analyst estimate. Raises FY2026 sales outlook from $3.295 billion-$3.350 billion to $3.345…
benzinga.com West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 analyst estimate..- benzinga.com West Pharmaceutical Servs Sees Q3 Adj EPS $2.14-$2.24 vs $2.12 Est; Sees Sales $820.000M-$835.000M vs $815.707M Est West Pharmaceutical Servs (NYSE:WST) is looking for Q3 Adj EPS of $2.14-$2.24 vs $2.12 analyst estimate. sees sales of $820.000 million-$835.000 million vs $815.707 million analyst estimate.
- benzinga.com West Pharmaceutical Servs Q2 Adj. EPS $2.37 Beats $2.08 Estimate, Sales $872.300M Beat $838.586M Estimate West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.08 by 13.94 percent. This is a 28.8 percent increase over earnings…
- benzinga.com West Pharmaceutical Services Enters Into Multiple Amended Distribution And Crosslicensing Agreements With Daikyo Seiko https://www.sec.gov/ix?doc=/Archives/edgar/data/0000105770/000010577026000093/wst-20260714.htmThe terms of the Agreements are substantially similar to the terms of the Amended and Restated Technology…
- benzinga.com BNP Paribas Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $447 BNP Paribas analyst Curtis Moiles initiates coverage on West Pharmaceutical Servs (NYSE:WST) with a Outperform rating and announces Price Target of $447.
- benzinga.com Morgan Stanley Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $365 Morgan Stanley analyst Kallum Titchmarsh maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $325 to $365.
- benzinga.com Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $410 Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $390 to $410.
- benzinga.com Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $390 Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $350 to $390.
benzinga.com This Brady Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Wall Street analysts upgraded AJG & BRC. See analyst rating changes & how they view BRC stock.